FAQ

Discontinuation (procedure)

Known as: discontinuation, discontinuations 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1978-2018
010020019782018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Improved overall survival in melanoma with combined dabrafenib and trametinib.
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
BACKGROUND Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Boceprevir for untreated chronic HCV genotype 1 infection.
BACKGROUND Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Sclerostin, an osteocyte-secreted protein, negatively regulates osteoblasts and inhibits bone formation. In this first-in-human… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
BACKGROUND Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
BACKGROUND Several studies have shown the efficacy, tolerability, and ease of administration of pemetrexed-an antifolate… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving…
OBJECTIVE Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with…
BACKGROUND ACE inhibitors attenuate the detrimental effects of angiotensin II, and improve survival and reduce morbidity in… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
CONTEXT Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402… (More)
  • table 1
  • figure 1
  • table 3
  • table 2
  • table 4
Is this relevant?